Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
NaMiX
- Development stage
- Preclinical
- Lead developer
- Inserm
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, scFv Fragments → Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics, Cytokines & Interferons → Recombinant Proteins and Enzymes
- Administration
- Intravenous
01
Overview
NaMiX (Natural Killer activating multimeric immunotherapeutic complexes) is an experimental immunotherapeutic agent designed to reactivate Natural Killer (NK) cells. It consists of IL-15/IL-15Rα dimers coupled to single-chain variable fragments (scFvs) targeting the NK cell activating receptor NKp46. By providing both a potent cytokine stimulus (IL-15) and a direct activating signal through NKp46, NaMiX aims to restore the cytotoxic function and infiltration of NK cells within the hostile tumor microenvironment of pancreatic ductal adenocarcinoma (PDAC). In preclinical models, it has demonstrated the ability to expand cytotoxic lymphocytes and enhance tumor infiltration, particularly when combined with tumor-targeting engagers like TriKE.
- Other names
- Natural Killer activating multimeric immunotherapeutic complexes
02
Targets
IL15 (Interleukin 15)IL2RB (IL-2 receptor beta chain)IL15RA (Interleukin-15 receptor subunit alpha)NCR1 (Natural cytotoxicity triggering receptor 1)
Beyond the preview
Go deeper on NaMiX.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on NaMiX.